<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d752e6b5-5f7d-4a9e-bde2-cd468e01c22a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use OMNISCAN safely and effectively. See full prescribing information for OMNISCAN.<br/>
      <br/>
      <br/>
      <br/>OMNISCAN™ (gadodiamide) Injection for Intravenous Use<br/>
      <br/>Initial U.S. Approval: 1993</title>
   <effectiveTime value="20250311"/>
   <setId root="1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a"/>
   <versionNumber value="23"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="053046579"/>
            <name>GE Healthcare Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="515048908"/>
                        <name>GE Healthcare AS</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="ANALYSIS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="988006565"/>
                        <name>GE Healthcare Ireland Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="545292716"/>
                        <name>GE Healthcare Shanghai Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="518890970"/>
                        <name>GE Healthcare AS</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="74ccd450-3557-439e-8760-51cd44e07ec8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250311"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0407-0690" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>OMNISCAN</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>gadodiamide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="12"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1M6415C70M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALDIAMIDE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="287"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="84F6U3J2R6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GADODIAMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="84F6U3J2R6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GADODIAMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-0690-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20020419"/>
                                          <high value="20250727"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-0690-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20020419"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-0690-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20020419"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-0690-20" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20020419"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43204" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-0690-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20020419"/>
                                          <high value="20230929"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43204" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-0690-17" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20020419"/>
                                          <high value="20230930"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43204" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0407-0690-22" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20020419"/>
                                          <high value="20230804"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020123" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20020419"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>Clear, colorless to slightly yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="093a73bc-fc89-4769-a5d9-17df441c2c1c"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS</title>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. OMNISCAN is not approved  for intrathecal use (</content>
                              <linkHtml href="#S5.1">5.1</linkHtml>
                              <content styleCode="bold">).</content>
                           </item>
                           <item>
                              <content styleCode="bold">GBCAs increase the risk for nephrogenic systemic fibrosis among patients with impaired elimination of the drugs.  Avoid use of OMNISCAN in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. Do not administer OMNISCAN to patients with:</content>
                              <list listType="unordered" styleCode="circle">
                                 <item>
                                    <content styleCode="bold">chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m<sup>2</sup>), or</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">acute kidney injury (</content>
                                    <linkHtml href="#S4">4</linkHtml>
                                    <content styleCode="bold">).</content>
                                 </item>
                              </list>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Screen patients for acute kidney injury and other conditions that may reduce renal function.  For patients at risk for chronically reduced renal function (e.g., age &gt; 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing (</content>
                           <linkHtml href="#S5.2">5.2</linkHtml>
                           <content styleCode="bold">).</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="8372d9f1-abc4-446b-bc8a-750ecad84f71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Risk Associated with Intrathecal Use</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. OMNISCAN is not approved for intrathecal use </content>
                           <content styleCode="bold italics">[see<linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="95d7567f-4ce5-48e6-8471-0d242e73a71b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Nephrogenic Systemic Fibrosis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of OMNISCAN in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Do not administer OMNISCAN to patients with:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Circle">
                           <item>
                              <content styleCode="bold">chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m<sup>2</sup>), or</content>
                           </item>
                           <item>
                              <content styleCode="bold">acute kidney injury </content>
                              <content styleCode="bold italics">[see<linkHtml href="#S4"> Contraindications (4)</linkHtml>].</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., age &gt; 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Do not exceed the recommended OMNISCAN dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration </content>
                           <content styleCode="bold italics">[see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="79858c92-e9dc-4eff-8306-a3cdad77aaf9"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>OMNISCAN is a gadolinium-based contrast agent for diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Visualize lesions with abnormal vascularity in the brain, spine, and associated tissues (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>Facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="d6419493-f3c6-4436-9854-c01ef06bf490"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	CNS (Central Nervous System)</title>
                     <text>
                        <paragraph>OMNISCAN is a gadolinium-based contrast agent indicated for intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues <content styleCode="italics">[see<linkHtml href="#S14.1"> Clinical Studies (14.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="92ab0938-712b-4ec1-aa02-b2c6ac2ed9a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Body (Intrathoracic [noncardiac], Intra-abdominal, Pelvic and Retroperitoneal Regions)</title>
                     <text>
                        <paragraph>OMNISCAN is a gadolinium-based contrast agent indicated for intravenous use in MRI to facilitate the visualization of lesions with abnormal vascularity within the thoracic (noncardiac), abdominal, pelvic cavities, and the retroperitoneal space <content styleCode="italics">[see<linkHtml href="#S14.2"> Clinical Studies (14.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="df1c403b-2821-47b8-9d4b-6ef55dc421c5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>CNS – Adults and Pediatrics; 2 to 16 years of age: 0.2 mL/kg<br/>(0.1 mmol/kg) (<linkHtml href="#S2.1">2.1</linkHtml>,<linkHtml href="#S2.4"> 2.4</linkHtml>)</item>
                           <item>Body – Adults and Pediatrics; 2 to 16 years of age:<list listType="unordered" styleCode="circle">
                                 <item>Kidney: 0.1 mL/kg (0.05 mmol/kg)</item>
                                 <item>Intrathoracic, intra-abdominal, and pelvic cavities: 0.2 mL/kg <br/>(0.1 mmol/kg) (<linkHtml href="#S2.2">2.2</linkHtml>,<linkHtml href="#S2.4"> 2.4</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="0c8dae39-ccab-4311-877b-a577e53f1a2e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	CNS (Central Nervous System)</title>
                     <effectiveTime value="20250311"/>
                     <component>
                        <section>
                           <id root="cd704c59-b89e-4d7a-b071-0304bc535b90"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Adults: </content>
                                 </content>The recommended dose of OMNISCAN is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.</paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b06aa363-03f4-4899-881a-3cdfc88f17f5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Pediatric Patients (2 to 16 years of age): </content>
                                 </content>The recommended dose of OMNISCAN is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection <content styleCode="italics">[see<linkHtml href="#S2.3"> Dosage and Administration (2.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="b8d8a9d8-d3bd-4d80-aff0-94dc10f1eef1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Body (Intrathoracic [noncardiac], Intra-abdominal, Pelvic and Retroperitoneal Regions)</title>
                     <effectiveTime value="20250311"/>
                     <component>
                        <section>
                           <id root="d1b0a6be-86e1-445a-9405-0892fe51c0ec"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Adult and Pediatric Patients (2 to 16 years of age): </content>
                                 </content>For imaging the kidney, the recommended dose of OMNISCAN is 0.1 mL/kg (0.05 mmol/kg). For imaging the intrathoracic (noncardiac), intra-abdominal, and pelvic cavities, the recommended dose of OMNISCAN is 0.2 mL/kg (0.1 mmol/kg) <content styleCode="italics">[see<linkHtml href="#S2.3"> Dosage and Administration (2.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="2a98ec5c-c54c-4ffa-bdde-bc713a99c67f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage Chart</title>
                     <text>
                        <table width="75%">
                           <col width="17%" align="center" valign="top"/>
                           <col width="16%" align="center" valign="top"/>
                           <col width="17%" align="center" valign="top"/>
                           <col width="16%" align="center" valign="top"/>
                           <col width="17%" align="center" valign="top"/>
                           <col width="17%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th colspan="2" styleCode="Lrule Rrule">BODY WEIGHT</th>
                                 <th colspan="2" styleCode="Rrule">PEDIATRIC</th>
                                 <th colspan="2" styleCode="Rrule">ADULTS</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule"/>
                                 <th styleCode="Rrule"/>
                                 <th styleCode="Lrule">0.05</th>
                                 <th styleCode="Rrule">0.1</th>
                                 <th styleCode="Lrule">0.05</th>
                                 <th styleCode="Rrule">0.1</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule">kg</th>
                                 <th styleCode="Rrule">lb</th>
                                 <th colspan="2" styleCode="Rrule Botrule">(mmol/kg)</th>
                                 <th colspan="2" styleCode="Rrule Botrule">(mmol/kg)</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule"/>
                                 <th styleCode="Rrule"/>
                                 <th colspan="2" styleCode="Rrule">VOLUME (mL)</th>
                                 <th colspan="2" styleCode="Rrule">VOLUME (mL)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">12</td>
                                 <td styleCode="Rrule">26</td>
                                 <td styleCode="Rrule">1.2</td>
                                 <td styleCode="Rrule">2.4</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">14</td>
                                 <td styleCode="Rrule">31</td>
                                 <td styleCode="Rrule">1.4</td>
                                 <td styleCode="Rrule">2.8</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">16</td>
                                 <td styleCode="Rrule">35</td>
                                 <td styleCode="Rrule">1.6</td>
                                 <td styleCode="Rrule">3.2</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">18</td>
                                 <td styleCode="Rrule">40</td>
                                 <td styleCode="Rrule">1.8</td>
                                 <td styleCode="Rrule">3.6</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">20</td>
                                 <td styleCode="Rrule">44</td>
                                 <td styleCode="Rrule">2</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">22</td>
                                 <td styleCode="Rrule">48</td>
                                 <td styleCode="Rrule">2.2</td>
                                 <td styleCode="Rrule">4.4</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">24</td>
                                 <td styleCode="Rrule">53</td>
                                 <td styleCode="Rrule">2.4</td>
                                 <td styleCode="Rrule">4.8</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">26</td>
                                 <td styleCode="Rrule">57</td>
                                 <td styleCode="Rrule">2.6</td>
                                 <td styleCode="Rrule">5.2</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">28</td>
                                 <td styleCode="Rrule">62</td>
                                 <td styleCode="Rrule">2.8</td>
                                 <td styleCode="Rrule">5.6</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">30</td>
                                 <td styleCode="Rrule">66</td>
                                 <td styleCode="Rrule">3</td>
                                 <td styleCode="Rrule">6</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">40</td>
                                 <td styleCode="Rrule">88</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">8</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">8</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">50</td>
                                 <td styleCode="Rrule">110</td>
                                 <td styleCode="Rrule">5</td>
                                 <td styleCode="Rrule">10</td>
                                 <td styleCode="Rrule">5</td>
                                 <td styleCode="Rrule">10</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">60</td>
                                 <td styleCode="Rrule">132</td>
                                 <td styleCode="Rrule">6</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">6</td>
                                 <td styleCode="Rrule">12</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">70</td>
                                 <td styleCode="Rrule">154</td>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">14</td>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">14</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">80</td>
                                 <td styleCode="Rrule">176</td>
                                 <td styleCode="Rrule">8</td>
                                 <td styleCode="Rrule">16</td>
                                 <td styleCode="Rrule">8</td>
                                 <td styleCode="Rrule">16</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">90</td>
                                 <td styleCode="Rrule">198</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">9</td>
                                 <td styleCode="Rrule">18</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">100</td>
                                 <td styleCode="Rrule">220</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">10</td>
                                 <td styleCode="Rrule">20</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">110</td>
                                 <td styleCode="Rrule">242</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">11</td>
                                 <td styleCode="Rrule">22</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">120</td>
                                 <td styleCode="Rrule">264</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">24</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">130<footnote ID="f1">The heaviest patient in clinical studies weighed 136 kg.</footnote>
                                 </td>
                                 <td styleCode="Rrule">286</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule">26</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="9e78c29c-ff19-44a3-9af0-bcfd21e48b42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4    Dosing Guidelines</title>
                     <text>
                        <paragraph>Inspect OMNISCAN visually for particulate matter and discoloration before administration, whenever solution and container permit. Do not use the solution if it is discolored or particulate matter is present.</paragraph>
                        <paragraph>Draw OMNISCAN into the syringe and use immediately. Discard any unused portion of OMNISCAN Injection.</paragraph>
                        <paragraph>To ensure complete delivery of the desired volume of contrast medium, follow the injection of OMNISCAN with a 5 mL flush of 0.9% sodium chloride. Complete the imaging procedure within 1 hour of administration of OMNISCAN.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="7122ecac-80f4-4aab-8d3e-7ed8fbb33e1f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Sterile aqueous solution for intravenous injection; 287 mg/mL.</paragraph>
               </text>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sterile aqueous solution for intravenous injection; 287 mg/mL (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="a7dd165e-4d65-4217-b2f4-6ded1f89d369"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>OMNISCAN is contraindicated in patients with:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Chronic, severe kidney disease (glomerular filtration rate, GFR &lt; 30 mL/min/1.73m<sup>2</sup>) or acute kidney injury  </item>
                     <item>Prior hypersensitivity to OMNISCAN</item>
                  </list>
               </text>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m<sup>2</sup>) or acute kidney injury (<linkHtml href="#S4">4</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="ef69d822-4a7e-47fd-bb75-c8d9f8a3935e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>	Hypersensitivity Reactions: Anaphylactoid and other serious hypersensitivity reactions including fatal reactions have occurred particularly in patients with history of allergy  or  drug   reactions.   Monitor   patients  closely  for  need  of emergency cardiorespiratory support (<linkHtml href="#S5.3">5.3</linkHtml>).</item>
                           <item>Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs (<linkHtml href="#S5.4">5.4</linkHtml>).</item>
                           <item>Acute Renal Failure: Acute renal failure has occurred in patients with preexisting renal insufficiency. Use the lowest necessary dose of OMNISCAN and evaluate renal function in these patients (<linkHtml href="#S5.5">5.5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="c502da80-b93a-4c1e-bf85-a8f2d93debe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1    Risk Associated with Intrathecal Use</title>
                     <text>
                        <paragraph>Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of OMNISCAN have not been established with intrathecal use. OMNISCAN is not approved for intrathecal use <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.2">2.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="e3d997bb-f5fd-4e38-a06f-0b5265983769"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2    Nephrogenic Systemic Fibrosis</title>
                     <text>
                        <paragraph>GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of OMNISCAN among these patients unless the diagnostic information is essential and not available with non-contrast enhanced MRI or other modalities. The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m<sup>2</sup>) as well as patients with acute kidney injury. Do not administer OMNISCAN to these patients. The risk appears lower for patients with chronic, moderate kidney disease (GFR 30 to 59 mL/min/1.73m<sup>2</sup>) and little, if any, for patients with chronic, mild kidney disease (GFR 60 to 89 mL/min/1.73m<sup>2</sup>). NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Report any diagnosis of NSF following OMNISCAN administration to GE HealthCare (1-800-654-0118) or FDA (1-800-FDA-1088 or www.fda.gov/medwatch).</paragraph>
                        <paragraph>Screen patients for acute kidney injury and other conditions that may reduce renal function. Features of acute kidney injury consist of rapid (over hours to days) and usually reversible decrease in kidney function, commonly in the setting of surgery, severe infection, injury or drug-induced kidney toxicity. Serum creatinine levels and estimated GFR may not reliably assess renal function in the setting of acute kidney injury. For patients at risk for chronically reduced renal function (e.g., age &gt; 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing.</paragraph>
                        <paragraph>Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA and the degree of renal impairment at the time of exposure. Record the specific GBCA and the dose administered to a patient. When administering a GBCA, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent prior to any readministration <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>, <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml> and <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="126a860b-2136-4828-84ee-0f6ece6bc796"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3    Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Anaphylactoid and anaphylactic reactions, with cardiovascular, respiratory and/or cutaneous manifestations, resulting in death have occurred. Personnel trained in resuscitation techniques and resuscitation equipment should be present prior to OMNISCAN administration. If a hypersensitivity reaction occurs, stop OMNISCAN Injection and immediately begin appropriate therapy. Observe patients closely, particularly those with a history of drug reactions, asthma, allergy or other hypersensitivity disorders, during and up to several hours after OMNISCAN Injection.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="1f30da42-0ff1-4d0d-abd3-c59451facde0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Gadolinium Retention</title>
                     <text>
                        <paragraph>Gadolinium is retained for months or years in several organs. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (e.g., brain, skin, kidney, liver, and spleen). The duration of retention also varies by tissue and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, gadolinium retention varies among the linear agents with Omniscan (gadodiamide) and Optimark (gadoversetamide) causing greater retention than other linear agents [Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), MultiHance (gadobenate dimeglumine)]. Retention is lowest and similar among the macrocyclic GBCAs [Dotarem (gadoterate meglumine), Gadavist (gadobutrol), ProHance (gadoteridol)].</paragraph>
                        <paragraph>Consequences of gadolinium retention in the brain have not been established. Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function <content styleCode="italics">[see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>].</content> There are rare reports of pathologic skin changes in patients with normal renal function. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention <content styleCode="italics">[see<linkHtml href="#S6.2"> Adverse Reactions (6.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients <content styleCode="italics">[see<linkHtml href="#S8.1"> Use in Specific Populations (8.1</linkHtml>,<linkHtml href="#S8.4"> 8.4)</linkHtml>],</content> and patients with inflammatory conditions. Consider the retention characteristics of the agent when choosing a GBCA for these patients. Minimize repetitive GBCA imaging studies, particularly closely spaced studies, when possible.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="c97f8dc0-f01e-4c37-9777-a721b48e70d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Acute Renal Failure</title>
                     <text>
                        <paragraph>In patients with renal insufficiency, acute renal failure requiring dialysis or worsening renal function have occurred, mostly within 48 hours of OMNISCAN Injection. The risk of renal failure may increase with increasing dose of gadolinium contrast. Use the lowest necessary dose of contrast and evaluate renal function in patients with renal insufficiency. Acute renal failure was observed in &lt; 1% of patients in OMNISCAN clinical studies <content styleCode="italics">[see<linkHtml href="#S6"> Adverse Reactions (6)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>OMNISCAN is cleared by glomerular filtration. Hemodialysis also enhances OMNISCAN clearance <content styleCode="italics">[see<linkHtml href="#S8.5"> Use in Specific Populations (8.5</linkHtml>,<linkHtml href="#S8.6"> 8.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="f942db39-5c09-4c0e-b7b0-e793b7b77139"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Impaired Visualization of Lesions Detectable with Non-contrast MRI</title>
                     <text>
                        <paragraph>Paramagnetic contrast agents such as OMNISCAN might impair the visualization of lesions which are seen on the non-contrast MRI. This may be due to effects of the paramagnetic contrast agent, or imaging parameters. Exercise caution when OMNISCAN MRI scans are interpreted in the absence of a companion non-contrast MRI.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="927127ca-f429-4000-b77e-de772e012c9f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Laboratory Test Findings</title>
                     <text>
                        <paragraph>Asymptomatic, transitory changes in serum iron have been observed. The clinical significance is unknown.</paragraph>
                        <paragraph>OMNISCAN interferes with serum calcium measurements with some colorimetric (complexometric) methods commonly used in hospitals, resulting in serum calcium concentrations lower than the true values. In patients with normal renal function, this effect lasts for 12 to 24 hours. In patients with decreased renal function, the interference with calcium measurements is expected to last during the prolonged elimination of OMNISCAN. After patients receive OMNISCAN, careful attention should be used in selecting the type of method used to measure calcium.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="adf66f91-6fd3-451d-8930-9a40859fbee1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in greater detail in other sections of the label:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Nephrogenic systemic fibrosis <content styleCode="italics">[see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity reactions <content styleCode="italics">[see<linkHtml href="#S5.3"> Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Acute Renal Failure <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The   most   frequent   adverse   reactions   (≤   3%)   observed   during OMNISCAN adult clinical studies were nausea, headache, and dizziness (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>Serious or life-threatening reactions include: cardiac failure, arrhythmia and myocardial infarction (<linkHtml href="#S6.1">6.1</linkHtml>,<linkHtml href="#S6.2"> 6.2</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 1-800-654-0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="9227b3b4-a76b-4cfb-bbce-a3469d3aba90"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                     <component>
                        <section>
                           <id root="f53701db-9e85-44ee-b4a6-507ce2d6370d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Adult Patients </content>
                              </paragraph>
                              <paragraph>In clinical studies 1,160 patients were exposed to OMNISCAN. The most frequent adverse reactions were nausea, headache, and dizziness that occurred in 3% or less of the patients. The majority of these reactions were of mild to moderate intensity.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">The following adverse reactions occurred in 1% or less of patients:</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Application Site Disorders: </content>Injection site reaction.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Autonomic Nervous System Disorders: </content>Vasodilation.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Body as a Whole-General Disorders: </content>Anaphylactoid  reactions  (characterized  by  cardiovascular,  respiratory,  and  cutaneous symptoms), fever, hot flushes, rigors, fatigue, malaise, pain, syncope.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiovascular Disorders: </content>Cardiac failure, rare arrhythmia and myocardial infarction resulting in death in patients with ischemic heart disease, flushing, chest pain, deep thrombophlebitis.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Central and Peripheral Nervous System Disorders: </content>Convulsions including grand mal, ataxia, abnormal coordination, paresthesia, tremor, aggravated multiple sclerosis (characterized by sensory and motor disturbances), aggravated migraine.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal System Disorders: </content>Abdominal pain, diarrhea, eructation, dry mouth/vomiting, melena.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hearing and Vestibular Disorders: </content>Tinnitus.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Liver and Biliary System Disorders: </content>Abnormal hepatic function.</paragraph>
                              <paragraph>
                                 <content styleCode="italics"> Musculoskeletal System Disorders: </content>Arthralgia, myalgia.</paragraph>
                              <paragraph>
                                 <content styleCode="italics"> Respiratory System Disorders: </content>Rhinitis, dyspnea.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Skin and Appendage Disorders: </content>Pruritus, rash, erythematous rash, sweating increased, urticaria. </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Special Senses, Other Disorders: </content>Taste loss, taste perversion.</paragraph>
                              <paragraph>
                                 <content styleCode="italics"> Urinary System Disorders: </content>Acute reversible renal failure.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Vision Disorders: </content>Abnormal vision.</paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="81eda290-88f8-4c84-ba07-cabd6d8ba919"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Pediatric Patients</content>
                              </paragraph>
                              <paragraph>In the 97 pediatric patients in CNS studies with OMNISCAN <content styleCode="italics">[see<linkHtml href="#S14.1"> Clinical Studies (14.1)</linkHtml>]</content> and the 144 pediatric patients in published literature, the adverse reactions were similar to those reported in adults.</paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="ec2a22d6-8651-4a08-9fc3-718c490a1aa4"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The  following adverse reactions have been identified during post-approval use of OMNISCAN or other GBCAs.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> Acute pancreatitis with onset within 48 hours after GBCA administration<content styleCode="underline">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders</content>: Nephrogenic Systemic Fibrosis (NSF)</paragraph>
                        <paragraph>Adverse reactions  with variable onset and duration have been reported after GBCA administration<content styleCode="italics">.</content> These include fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> Convulsions in patients with and without a history of convulsions or brain lesions.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders</content>: Acute respiratory distress syndrome, pulmonary edema</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary System Disorders: </content>In patients with pre-existing renal insufficiency: acute renal failure, renal impairment, blood creatinine increased<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin</content>: Gadolinium-associated plaques.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="fde18650-2d02-4356-830d-0e967d52fbcb"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Specific drug interaction studies have not been conducted.</paragraph>
               </text>
               <effectiveTime value="20250311"/>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="ede7f4dc-b41c-40b1-99da-6f47f3ff55be"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250311"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy: Use only if imaging is essential during pregnancy and cannot be delayed (<linkHtml href="#S8.1">8.1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="082f68ed-70fd-44a1-85e7-0ea623d07500"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250311"/>
                     <component>
                        <section>
                           <id root="abcc93ef-b9f5-44de-ac05-6d7263e297a7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. In animal reproduction studies, no adverse fetal effects were observed with administration of gadodiamide to pregnant rats during organogenesis at doses 1.3 times the maximum human dose based on body surface area <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. Because of the potential risks of gadolinium to the fetus, use OMNISCAN only if imaging is essential during pregnancy and cannot be delayed.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="a61f26b6-fb7f-4a00-8763-310604b3d90e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                           <component>
                              <section>
                                 <id root="f85341e0-3fae-4136-9a43-57262b974872"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Contrast enhancement is visualized in the human placenta and fetal tissues after maternal GBCA administration.</paragraph>
                                    <paragraph>Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported a clear association between GBCAs and adverse effects in the exposed neonates. However, a retrospective cohort study, comparing pregnant women who had a GBCA MRI to pregnant women who did not have an MRI, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include a lack of comparison with non-contrast MRI and lack of information about the maternal indication for MRI. Overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy.</paragraph>
                                 </text>
                                 <effectiveTime value="20250311"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="0041f1fa-da7a-4a4e-933e-bd63e95882dd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250311"/>
                                 <component>
                                    <section>
                                       <id root="9bfde04c-fd66-4750-aefc-b5b4e94caa56"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Gadolinium Retention</content>
                                          </paragraph>
                                          <paragraph>GBCAs administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. GBCAs administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one-month postnatal age.</paragraph>
                                       </text>
                                       <effectiveTime value="20250311"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="86daca5e-f5d6-49a1-9a0c-67ab41cda25c"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline">Reproductive Toxicology</content>
                                          </paragraph>
                                          <paragraph>Gadodiamide has been shown to have an adverse effect on embryo-fetal development in rabbits at dosages as low as 0.5 mmol/kg/day for 13 days during gestation (approximately 0.6 times the human dose based on a body surface area comparison). These adverse effects are observed as an increased incidence of flexed appendages and skeletal malformations which may be due to maternal toxicity since the body weight of the dams was reduced in response to gadodiamide administration during pregnancy. In rat studies, fetal abnormalities were not observed at doses up to 2.5 mmol/kg/day for 10 days during gestation (1.3 times the maximum human dose based on a body surface area comparison); however, maternal toxicity was not achieved in these studies and a definitive conclusion about teratogenicity in rats at doses above 2.5 mmol/kg/day cannot be made.  </paragraph>
                                       </text>
                                       <effectiveTime value="20250311"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="fc93c8f5-285f-40ad-b756-25ebb5fffe1d"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250311"/>
                     <component>
                        <section>
                           <id root="04f40fec-3e93-4841-a824-2ba030f479eb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of gadodiamide in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is excreted in breast milk. Additionally, there is limited GBCA gastrointestinal absorption in the breast-fed infant. Animal data show transfer of gadodiamide into rat milk <content styleCode="italics">(see <linkHtml href="#data2">Data</linkHtml>).</content> The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for OMNISCAN and any potential adverse effects on the breastfed infant from OMNISCAN or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data2">
                           <id root="85ad4f97-7394-4f87-bc1a-b2f02695f05f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Gadodiamide is detected in the breast milk of rats injected intravenously with 0.3 mmol/kg up to 4 hours post dosing and is below the level of quantification after 8 hours.</paragraph>
                           </text>
                           <effectiveTime value="20250311"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="c691dcb4-20a4-47ad-833c-24d5386e1d55"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of OMNISCAN at a single dose of 0.05 to 0.1 mmol/kg have been established in pediatric patients over 2 years of age based on adequate and well controlled studies of OMNISCAN in adults, a pediatric CNS imaging study, and safety data in the scientific literature. However, the safety and efficacy of doses greater than 0.1 mmol/kg and of repeated doses have not been studied in pediatric patients.</paragraph>
                        <paragraph>Pharmacokinetics of OMNISCAN have not been studied in pediatrics. The glomerular filtration rate of neonates and infants is much lower than that of adults. The pharmacokinetics volume of distribution is also different. Therefore, the optimal dosing regimen and imaging times in patients under 2 years of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="9adf6a32-0081-472c-831f-9fb5538e4d6f"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In clinical studies of OMNISCAN, 243 patients were between 65 and 80 years of age while 15 were over 80 years of age. No overall differences in safety or effectiveness were observed between these patients and younger patients. Other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity in the elderly cannot be ruled out. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>OMNISCAN is excreted by the kidney, and the risk of toxic reactions to OMNISCAN may be greater in patients with impaired renal function <content styleCode="italics">[see<linkHtml href="#S5.4"> Warnings and Precautions (5.4)</linkHtml>].</content> Because elderly patients are more likely to have decreased renal function, select dose carefully and consider assessment of renal function before OMNISCAN use.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="c20bcede-560a-479c-bb2f-907b7153dd96"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6    Renal/Hepatic Impairment</title>
                     <text>
                        <paragraph>Dose adjustments in renal or hepatic impairment have not been studied. Caution should be exercised in patients with impaired renal insufficiency <content styleCode="italics">[see<linkHtml href="#S5.2"> Warnings and Precautions (5.2</linkHtml>,<linkHtml href="#S5.5"> 5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="a7bfd13a-629a-48f0-9baf-e39024b75c29"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Clinical consequences of overdose with OMNISCAN have not been reported. The minimum lethal dose of intravenously administered OMNISCAN in rats and mice is greater than 20 mmol/kg (200 times the recommended human dose of 0.1 mmol/kg; 67 times the cumulative 0.3 mmol/kg dose). OMNISCAN is dialyzable.</paragraph>
               </text>
               <effectiveTime value="20250311"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="3a141782-aa16-495d-9ebe-98fe0f0f239f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>OMNISCAN  (gadodiamide)  Injection  is  the  formulation  of  the  gadolinium  complex  of  diethylenetriamine  pentaacetic  acid bismethylamide, and is an injectable, nonionic extracellular enhancing agent for magnetic resonance imaging. OMNISCAN is administered by intravenous injection.</paragraph>
                  <paragraph>OMNISCAN is provided as a sterile, clear, colorless to slightly yellow, aqueous solution. Each 1 mL contains 287 mg gadodiamide and 12 mg caldiamide sodium in Water for Injection. The pH is adjusted between 5.5 and 7.0 with hydrochloric acid and/or sodium hydroxide. OMNISCAN contains no antimicrobial preservative. OMNISCAN is a 0.5 mol/L solution of aqua[5,8-bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oato (3-)-N<sup>5</sup>, N<sup>8</sup>, N<sup>11</sup>, O<sup>3</sup>, O<sup>5</sup>, O<sup>8</sup>, O<sup>11</sup>, O<sup>13</sup>] gadolinium hydrate, with a molecular weight of 573.66 (anhydrous), an empirical formula of C<sub>16</sub>H<sub>28</sub>GdN<sub>5</sub>O<sub>9</sub>∙xH<sub>2</sub>O, and the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Pertinent physicochemical data for OMNISCAN are noted below:</paragraph>
                  <table width="50%">
                     <caption>PARAMETER</caption>
                     <col width="60%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td>Osmolality (mOsmol/kg water)</td>
                           <td>@ 37°C</td>
                           <td>789</td>
                        </tr>
                        <tr>
                           <td>Viscosity (cP)</td>
                           <td>@ 20°C</td>
                           <td>2</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td/>
                           <td>@ 37°C</td>
                           <td>1.4</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td>Density (g/mL)</td>
                           <td>@ 25°C</td>
                           <td>1.14</td>
                        </tr>
                        <tr>
                           <td>Specific gravity</td>
                           <td>@ 25°C</td>
                           <td>1.15</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>OMNISCAN has an osmolality approximately 2.8 times that of plasma at 37°C and is hypertonic under conditions of use.</paragraph>
               </text>
               <effectiveTime value="20250311"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omniscan-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="ab8ee1d6-efc2-40fe-8b7c-9cb41a1c894a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250311"/>
               <component>
                  <section ID="S12.2">
                     <id root="fcb96351-77b3-43ff-81e4-75b47a7476ba"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>In magnetic resonance imaging, visualization of normal and pathologic tissue depends in part on variations in the radiofrequency signal intensity. These variations occur due to: changes in proton density; alteration of the spin-lattice or longitudinal relaxation time (T<sub>1</sub>); and variation of the spin-spin or transverse relaxation time (T<sub>2</sub>). OMNISCAN is a paramagnetic agent with unpaired electron spins which generate a local magnetic field. As water protons move through this local magnetic field, the changes in magnetic field experienced by the protons reorient them with the main magnetic field more quickly than in the absence of a paramagnetic agent.</paragraph>
                        <paragraph>By increasing the relaxation rate, OMNISCAN decreases both the T<sub>1 </sub>and T<sub>2 </sub>relaxation times in tissues where it is distributed. At clinical doses, the effect is primarily on the T<sub>1 </sub>relaxation time, and produces an increase in signal intensity. Disruption of the blood-brain barrier or abnormal vascularity allows accumulation of OMNISCAN in lesions such as neoplasms, abscesses, and subacute infarcts. The pharmacokinetic parameters of OMNISCAN in various lesions are not known. </paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="b98dd69e-8e7c-4eef-8018-3530e9248111"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of intravenously administered gadodiamide in normal subjects conforms to an open, two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively. Gadodiamide is eliminated primarily in the urine with 95.4 ± 5.5% (mean ± SD) of the administered dose eliminated by 24 hours. The renal and plasma clearance rates of gadodiamide are nearly identical (1.7 and 1.8 mL/min/kg, respectively), and are similar to that of substances excreted primarily by glomerular filtration. The volume of distribution of gadodiamide (200 ± 61 mL/kg) is equivalent to that of extracellular water. Gadodiamide does not bind to human serum proteins<content styleCode="italics"> in vitro. </content>Following GBCA administration, gadolinium is present for months or years in brain, bone, skin, and other organs <content styleCode="italics">[see<linkHtml href="#S5.4"> Warnings and Precautions (5.4)</linkHtml>].</content> Pharmacokinetic and pharmacodynamic studies have not been systematically conducted to determine the optimal dose and imaging time in patients with abnormal renal function or renal failure, in the elderly, or in pediatric patients with immature renal function.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="31272592-cc53-4e1b-affd-6ae09646dcbb"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250311"/>
               <component>
                  <section ID="S13.1">
                     <id root="c44e9a56-3315-42e2-adc3-c0caa32aae46"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long term animal studies have not been performed to evaluate the carcinogenic potential of gadodiamide. The results of the following genotoxicity assays were negative:<content styleCode="italics"> in vitro </content>bacterial reverse mutation assay,<content styleCode="italics"> in vitro </content>Chinese Hamster Ovary (CHO)/Hypoxanthine Guanine Phosphoribosyl Transferase (HGPT) forward mutation assay,<content styleCode="italics"> in vitro </content>CHO chromosome aberration assay, and the<content styleCode="italics"> in vivo </content>mouse micronucleus assay at intravenous doses of 27 mmol/kg (approximately 7 times the maximum human dose based on a body surface area comparison). Impairment of male or female fertility was not observed in rats after intravenous administration three times per week at the maximum dose tested of 1.0 mmol/kg (approximately 0.5 times the maximum human dose based on a body surface area comparison).</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="a82955b0-3338-4c01-b638-7b417672ce38"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250311"/>
               <component>
                  <section ID="S14.1">
                     <id root="1faa4a07-7486-4672-abbf-c2effc49a7cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1  CNS (Central Nervous System)</title>
                     <text>
                        <paragraph>OMNISCAN (0.1 mmol/kg) contrast enhancement in CNS MRI was evident in a study of 439 adults. In a study of sequential dosing, 57 adults received OMNISCAN 0.1 mmol/kg followed by 0.2 mmol/kg within 20 minutes (for cumulative dose of 0.3 mmol/kg). The MRIs were compared blindly. In 54/56 (96%) patients, OMNISCAN contrast enhancement was evident with both the 0.1 mmol/kg and cumulative 0.3 mmol/kg OMNISCAN doses relative to non-contrast MRI.</paragraph>
                        <paragraph>In comparison to the non-contrast MRI, increased numbers of brain and spine lesions were noted in 42% of patients who received OMNISCAN at any dose. In comparisons of 0.1 mmol/kg versus 0.3 mmol/kg, the results were comparable in 25/56 (45%); in 1/56 (2%) OMNISCAN 0.1 mmol/kg dose provided more diagnostic value and in 30/56 (54%) the cumulative OMNISCAN 0.3 mmol/kg dose provided more diagnostic value. The usefulness of a single 0.3 mmol/kg bolus in comparison to the cumulative 0.3 mmol/kg (0.1 mmol/kg followed by 0.2 mmol/kg) has not been established.</paragraph>
                        <paragraph>OMNISCAN as a single 0.1 mmol/kg dose was evaluated in 97 pediatric patients with a mean age of 8.9 (2 to 18) years referred for CNS MRI. Postcontrast MRI provided added diagnostic information, diagnostic confidence, and new patient management information in 76%, 67%, and 52%, respectively, of pediatrics.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="9cdd4952-512a-4747-bcbe-e907a06c0f0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2  Body (Intrathoracic [noncardiac], Intra-abdominal, Pelvic and Retroperitoneal Regions)</title>
                     <text>
                        <paragraph>OMNISCAN was evaluated in a controlled trial of 276 patients referred for body MRI. These patients had a mean age of 57 (9 to 88) years. Patients received 0.1 mmol/kg OMNISCAN for imaging the thorax (noncardiac), abdomen, and pelvic organs, or a dose of 0.05 mmol/kg for imaging the kidney. Pre- and post-OMNISCAN images were evaluated blindly for the degree of diagnostic value rated on a scale of "remarkably improved, improved, no change, worse, and cannot be determined." The postcontrast results showed "remarkably improved" or "improved" diagnostic value in 90% of the thorax, liver, and pelvis patients, and in 95% of the kidney patients. In a dose ranging study 258 patients referred for body MRI received OMNISCAN 0.025, 0.05, 0.1 mmol/kg. The lowest effective dose of OMNISCAN for the kidney was 0.05 mmol/kg.</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="64263f16-9831-4b9a-8c3d-60bd1efd3e47"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>OMNISCAN (gadodiamide) Injection is a sterile, clear, colorless to slightly yellow, aqueous solution containing 287 mg/mL of gadodiamide in rubber stoppered vials. OMNISCAN is supplied in the following sizes:</paragraph>
                  <paragraph>10 mL vial, box of 10 (NDC 0407-0690-10) <br/>15 mL fill in 20 mL vial, box of 10 (NDC 0407-0690-15) <br/>20 mL vial, box of 10 (NDC 0407-0690-20)</paragraph>
               </text>
               <effectiveTime value="20250311"/>
               <component>
                  <section>
                     <id root="e3c8db6d-1542-4da5-ae09-d27998176171"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Protect OMNISCAN from strong daylight and direct exposure to sunlight.<content styleCode="bold"> Do not freeze. </content>Freezing can cause small cracks in the vials, which would compromise the sterility of the product. Do not use if the product is inadvertently frozen.</paragraph>
                        <paragraph>Store OMNISCAN at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP].</paragraph>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="40438f8b-ab62-4437-b009-022ed2b326be"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>Patients receiving OMNISCAN should be instructed to inform their physician if they:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>are pregnant or breast feeding, or</item>
                     <item>have a history of renal and/or liver disease, convulsions, asthma or allergic respiratory disorders, or recent administration of gadolinium-based contrast.</item>
                  </list>
                  <paragraph>GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. To counsel patients at risk for NSF:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Describe the clinical manifestations of NSF</item>
                     <item>Describe procedures to screen for the detection of renal impairment</item>
                  </list>
                  <paragraph>Instruct the patients to contact their physician if they develop signs or symptoms of NSF following OMNISCAN administration such as burning, itching, swelling, scaling, hardening and tightening of the skin; red or dark patches on the skin; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; pain deep in the hip bones or ribs; or muscle weakness.</paragraph>
               </text>
               <effectiveTime value="20250311"/>
               <component>
                  <section>
                     <id root="f68ced28-cef8-46a2-8f56-3704f9c9e234"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>Gadolinium Retention</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise patients that gadolinium is retained for months or years in brain, bone, skin, and other organs in patients with normal renal function. The clinical consequences of retention are unknown. Retention depends on multiple factors and is greater following administration of linear GBCAs than following administration of macrocyclic GBCAs <content styleCode="italics">[see<linkHtml href="#S5.4"> Warnings and Precautions (5.4)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250311"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="7d9ee500-055f-42d5-991c-70ec5249fa40"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>© 2025 GE HealthCare<br/>Distributed by GE Healthcare Inc., Arlington Heights, IL 60004 U.S.A.<br/>GE is a trademark of General Electric Company used under trademark license.</paragraph>
               </text>
               <effectiveTime value="20250311"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b0685817-4a75-49ba-8f85-28c57eaf4d66"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="85%" align="left" valign="top"/>
                     <col width="15%" align="left" valign="top"/>
                     <thead>
                        <tr styleCode="Botrule">
                           <th align="center" colspan="2" styleCode="Lrule Rrule">MEDICATION GUIDE <br/>OMNISCAN™ (OMNI-scan) <br/>(gadodiamide) <br/>Injection, for intravenous use</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td>This Medication Guide has been approved by the U.S. Food and Drug Administration</td>
                           <td>Revised: 3/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <paragraph ID="impinf">
                                 <content styleCode="bold">What is the most important information I should know about OMNISCAN?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>GBCAs like OMNISCAN may cause serious side effects including death, coma, encephalopathy, and seizures when it is given intrathecally (injection given into the spinal canal). It is not known if OMNISCAN is safe and effective with intrathecal use. OMNISCAN is not approved for this use.</item>
                                 <item>OMNISCAN contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years).</item>
                                 <item>It is not known how gadolinium may affect you, so far, studies have not found harmful effects in patients with normal kidneys.</item>
                                 <item>Rarely, patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium.</item>
                                 <item>There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance. Gadolinium stays in the body the least after Dotarem, Gadavist, or ProHance.</item>
                                 <item>People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.</item>
                                 <item>Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive OMNISCAN.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold underline">What is OMNISCAN?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="underline">OMNISCAN is a prescription medicine called a gadolinium-based contrast agent (GBCA). OMNISCAN, like other GBCA medicines, is used with a magnetic resonance imaging (MRI) scanner.</content>
                                 </item>
                                 <item>
                                    <content styleCode="underline">An MRI exam with a GBCA, including OMNISCAN, helps your doctor to see problems better than an MRI exam without a GBCA.</content>
                                 </item>
                              </list>
                              <content styleCode="underline">Your doctor has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Do not receive OMNISCAN if you </content>have had a severe allergic reaction to OMNISCAN<content styleCode="bold">.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before receiving OMNISCAN, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if OMNISCAN can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as OMNISCAN is received during pregnancy</item>
                                 <item>have kidney problems, diabetes, or high blood pressure. </item>
                                 <item>have had an allergic reaction to dyes (contrast agents) including GBCAs </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of OMNISCAN?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">See "<linkHtml href="#impinf">What is the most important information I should know about OMNISCAN?</linkHtml>"</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Allergic reactions. OMNISCAN can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.</content>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of OMNISCAN include: nausea, headache, and dizziness. </content>
                              <br/>									These are not all the possible side effects of OMNISCAN.<br/>									Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of OMNISCAN.</content>
                              <br/>									Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about OMNISCAN that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in OMNISCAN?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient: </content>gadodiamide<br/>
                              <content styleCode="bold">Inactive ingredients: </content>caldiamide sodium, hydrochloric acid, sodium hydroxide<br/>© 2025 GE HealthCare<br/>Distributed by GE Healthcare Inc., Arlington Heights, IL 60004 U.S.A.<br/>GE is a trademark of General Electric Company used under trademark license.<br/>For more information, go to <content styleCode="underline">www.GEHealthCare.com</content> or call 1-800-654-0118.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250311"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ba9baae2-34da-41bd-b52e-35ebc0329056"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 10 mL Vial Label</title>
               <text>
                  <paragraph>NDC 0407-0690-10</paragraph>
                  <paragraph>OMNISCAN™<br/>(gadodiamide) Injection</paragraph>
                  <paragraph>10 mL<br/>287 mg/mL</paragraph>
                  <paragraph>10 mL Single-Dose Vial<br/>Sterile Aqueous Injection</paragraph>
                  <paragraph>Dispense the accompanying<br/>Medication Guide to each patient</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250311"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 10 mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="omniscan-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>